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THE SIGNIFICANCE OF ACUTE-PHASE SMALL-FOR-SIZE LIVER 
GRAFT INJURY IN MOBILIZATION OF CIRCULATING EPCS/
MDSCS/TREGS AFTER LDLT FOR HCC PATIENTS
K. Man1, Y. Shao1, K.T. Ng1, N. Wong2, X. Liu1, C. Li1, S. Fan1, C. Lo1  
1Department Of Surgery, The University of Hong Kong, Hong Kong/
HONG KONG, 2Antatomical And Cellular Pathology, Chinese 
University of Hong Kong, Hong Kong/HONG KONG
Introduction and Objective: Higher incidence of tumor recurrence 
is a major obstacle of living donor liver transplanatation (LDLT) 
for the patients with hepatocellular carcinoma (HCC). We have 
already demonstrated that acute phase small-for-size liver graft 
injury plays important role on late phase tumor recurrence and 
metastases in a serial animal studies. Understanding the molecular 
mechanism of acute phase small-for-size liver graft injury is essential 
for development of therapeutic strategy to reduce the likelihood of 
tumor recurrence after LDLT. In the current clinical study, we aim 
to investigate the impact of acute-phase small-for-size graft injury 
on mobilization of circulating endothelial progenitor cells (EPCs), 
myeloid-derived suppressive cells (MDSCs) and regulatory T cells 
(Tregs) in HCC patients after liver transplantation and to explore the 
molecular mechanism therein. 
Methods: From May 2000 to November 2009, 115 adult HCC 
recipients were included in the current study. The intragraft microRNA 
profiles of the grafts greater (Group 1) and less than 60% (Group 
2) of standard liver weight (SLW) were characterized by Low 
Density Array (LDA) analysis. Post-operative circulating EPCs 
(CD34+CD133+CD45-), MDSCs (CD34+CD13+CD33+) and Tregs 
(CD4+CD25+FOXP3+) were compared by FACS analysis. Intragraft 
hepatic stellate cell activation, macrophage infiltration and gene 
expression of Rac, Pyk2, Egr-1 and VEGF at the early phase after 
reperfusion were also detected by immunostaining and real-time RT-
PCR, respectively. Clinical-pathological data including the incidence 
of tumor recurrence and metastasis were compared between the two 
groups. Results: The patients were grouped into Group 1 (>= 60% 
SLW, n=37) and Group 2 (<60% SLW, n=78). The numbers of patients 
beyond Milan criteria [15/37(40.5%) vs 29/49(59.2%), p=0.838] 
or UCSF criteria [9/37(24.3%) vs 19/60(31.7%), p=1] were similar 
between the two groups. Much more patients in Group 2 developed 
tumor recurrence and lung metastasis [19/78(24.4%) vs 3/37(8%), 
p=0.04]. Level of circulating EPCs was significantly higher in Group 
2 (Day 3: 0.09% vs 0.002%, p=0.019; Week 4: 0.12% vs 0.033%, 
p=0.037; Week 8: 0.0585% vs 0.025%, p=0.018; Week 12: 0.055% 
vs 0.028%, p=0.025). A tendency of larger populations of circulating 
MDSCs and Tregs was also found in Group 2. Most of the patients 
with tumor recurrence had hepatic sinusoidal injury at early phase 
after liver transplantation. Significant activation of hepatic stellate 
cells was found in Group 2 together with stronger intragraft protein 
expression of FAK and CAK compared to Group 1. Intragraft mRNA 
levels of Egr-1, RhoA, FAK and VEGF were also significantly higher 
in Group 2. microRNA LDA analysis demonstrated that mir-233, 
mir-141, mir-1308, mir-548 and mir-576 were differentially expressed 
between the two groups. These mirRNAs were predicted to regulate 
targeting genes linked to graft injury (MAPK, CCL4 and Egr-1), tumor 
invasiveness (STAT5, CDC2 and EGFR), angiogenesis (VEGF, FLT4 
and ANGPTL5), and macrophage infiltration (MIP2). Conclusion: 
A significantly higher population of postoperative circulating EPCs, 
which are mobilized by small-for-size graft injury, may lead to a higher 
incidence of tumor recurrence and metastasis after LDLT. The distinct 
intragraft miRNA expression profile linked to acute-phase injury and 
angiogenesis may play a role in the mobilization of circulating EPCs, 
MDSCs, and Tregs. 
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 (Introduction)The major limitation of adult-to-adult living donor liver 
transplantation (AALDLT) is the adequacy of graft size and the issue 
of donor safety. It has been known that near 50% of the standard 
liver volume of the recipient is the minimally required graft volume 
to provide the adequate functional liver mass. A left lobe from the 
relatively small donor will not meet the metabolic demands of the 
larger recipient. The possible solution to this problem is to increase 
the extent of the donor’s liver resection by harvesting the right lobe, 
which accounts for more than 60% to 70% of total liver volume. 
However, the right lobe hepatectomy in the donor is not always safe, 
depending on the volume of the remaining left lobe. Not all donor can 
provide their right lobe because the safe donation is possible only 
when the future remnant liver volume is over 30%. As an alternative, 
dual left lobe from two living donors can solve the problem of graft-
size insufficiency and guarantee donor safety. In many occasions, 
the recipient’s body size is big, but the potential donors’ body size is 
small and their right lobe alone cannot meet the metabolic demand 
of the recipient. Dual transplantation with a right lobe and a left 
lobe will suffice the requirement of GRWR for this particular patient. 
(Method)From 2000 March to 2009 December, 291 Dual LDLTs 
were performed at our institute with 221 two left-lobes, 56 right + left 
lobes, and 14 posterior sector + left lobe. There were 62 emergent or 
urgent cases for fulminant and acute-on-chronic liver failure. (Results) 
In-hospital mortality occurred in 20 (6.8%) of 291 cases. Indications 
and survival outcomes of dual LDLT are comparable to those of 
single right-lobe LDLT. Although it seems to be complexed operation, 
it allows for provision of adequate graft mass for the recipients who 
would otherwise have no chance if only one donor were considered. 
By adding dual transplantation program, at least 12% increase of 
adult LDLT numbers can be anticipated.(Conclusion) The dual LDLT 
can provide sufficient graft volume without increasing donor risk.
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